IQ EQ FUND MANAGEMENT IRELAND Ltd Has $637,000 Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 137.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,657 shares of the company’s stock after purchasing an additional 31,626 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd owned 0.05% of Intellia Therapeutics worth $637,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Intellia Therapeutics during the 4th quarter worth about $43,177,000. Contrarius Group Holdings Ltd acquired a new position in Intellia Therapeutics in the fourth quarter worth approximately $11,798,000. State Street Corp raised its position in Intellia Therapeutics by 17.9% during the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after acquiring an additional 780,754 shares in the last quarter. Vanguard Group Inc. lifted its stake in Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company’s stock valued at $118,816,000 after acquiring an additional 562,249 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Intellia Therapeutics in the fourth quarter worth approximately $4,793,000. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating and set a $13.00 price target (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Truist Financial reduced their price target on Intellia Therapeutics from $90.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. The Goldman Sachs Group reissued a “sell” rating and set a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Citigroup raised their price objective on Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. Finally, HC Wainwright assumed coverage on Intellia Therapeutics in a research report on Wednesday, March 5th. They set a “buy” rating and a $30.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Trading Down 3.9 %

NTLA opened at $8.07 on Friday. The stock’s 50 day simple moving average is $9.98 and its 200-day simple moving average is $13.81. The stock has a market cap of $835.38 million, a PE ratio of -1.48 and a beta of 1.97. Intellia Therapeutics, Inc. has a 1 year low of $8.03 and a 1 year high of $28.18.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 29,000 shares of company stock worth $352,551 over the last 90 days. Corporate insiders own 3.20% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.